MORPHOSYS AG DGAP-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys to present MANIFEST and RE-MIND2 data from expanded hematology-oncology portfolio at the 2021 American Society of Hematology (ASH) Annual Meeting 2021-11-04 / 14:00 The issuer is solely responsible for the content of this announcement.
----------------------------------------------------------------------------------------------------------------------- MEDIA RELEASE
MorphoSys to present MANIFEST and RE-MIND2 data from expanded hematology-oncology portfolio at the 2021 American Society of Hematology (ASH) Annual Meeting
- Updates from MANIFEST phase 2 trial in patients with myelofibrosis, including clinical updates on JAK naïve patients treated with pelabresib in combination with ruxolitinib, including translational data
- MANIFEST update on pelabresib monotherapy in patients with myelofibrosis
- Expanded Real-World RE-MIND2 dataset comparing outcomes for tafasitamab plus lenalidomide versus pola-BR, R2, and CAR T in relapsed/refractory diffuse large B-Cell lymphoma PLANEGG/MUNICH, Germany - November 4, 2021 - MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that new data on approved and clinical-stage therapeutics will be presented during the American Society of Hematology (ASH) Annual Meeting from December 11-14 in Atlanta, Georgia United States. Ten abstracts were accepted, including two oral presentations, from the comprehensive MorphoSys portfolio, including abstracts for the BET inhibitor pelabresib, which MorphoSys added to its pipeline through the acquisition of Constellation Pharmaceuticals.
"MorphoSys continues to contribute significantly to scientific advances in hematology-oncology with our cancer immunotherapy and our expanded portfolio including the development of epigenetic modifiers," said Malte Peters, MD, MorphoSys Chief Research and Development Officer. "The important data published in our ASH presentations show our commitment to finding cures that redefine how cancer is treated."
The MANIFEST and RE-MIND2 presentations at ASH 2021 are the culmination of a transformational year for MorphoSys. Through groundbreaking proprietary research in immunotherapy and the addition of Constellation Pharmaceuticals' high-potential product candidates, MorphoSys has bolstered its position as an emerging leader in hematology-oncology.
Highlights of presentations from the MorphoSys hematology-oncology portfolio include:
- An update of clinical and translational data from the ongoing MANIFEST trial for JAK naïve patients treated with pelabresib (CPI-0610) in combination with ruxolitinib (study arm 3), representing the analysis for the primary endpoint SVR35
- An update of clinical and translational data from the ongoing MANIFEST trial for pelabresib (CPI-0610) monotherapy in patients with myelofibrosis
- Expanded Real-World RE-MIND2 dataset comparing tafasitamab and lenalidomide (Tafa+Len) outcomes to those observed in matched cohorts of 1) polatuzumab vedotin plus bendamustine and rituximab (pola-BR), 2) rituximab plus lenalidomide (R2); and 3) CAR-T therapies
Follow MorphoSys on Twitter via @MorphoSys and visit the MorphoSys ASH virtual booth at www.MorphoSysEvents.com
PELABRESIB ASH 2021 ACCEPTED ABSTRACTS
Study Abstract Title Authors Status / Publication #
/
Session
MANIFEST? Pelabresib (CPI-0610) Marina Kremyanskaya, John Mascarenhas, Francesca Oral Presentation
Monotherapy in Patients with Palandri, Alessandro M. Vannucchi, Srdan #141?
Myelofibrosis - Update of Verstovsek, Claire Harrison, Prithviraj Bose, Session Name: 634.
Clinical and Translational Data Gary J. Schiller, Raajit K. Rampal, Mark W. Myeloproliferative
from the Ongoing MANIFEST Trial Drummond, Vikas Gupta, Andrea Patriarca, Nikki Syndromes: Clinical and
? Granacher, Joseph Scandura, Witold Prejzner, Epidemiological:
Lino Teichmann, Natalia Curto-García, Ronald Non-JAK inhibitor
Hoffman, Gozde Colak, Zheng Ren, Suresh Bobba, Therapies for
Jike Cui, Sergey Efuni, Moshe Talpaz? Myelofibrosis ?
Session Date: Saturday,
December 11, 2021 ?
Session Time: 12:00 PM
- 1:30 PM ?
Presentation Time:
12:30 PM ?
Room: Georgia World
Congress Center,
A411-A412?
Pelabresib PK and PD Assessment of BET Kristie A. Blum, Jeffrey Supko, Michael Maris, POSTER
Ph1 ? Inhibitor Pelabresib (CPI-0610) Ian Flinn, Andre Goy, Anas Younes, Suresh Bobba, #?1202
in Patients With Relapsed or Adrian Senderowicz, Sergey Efuni, Ronda Rippley, Session Name: 605.
Refractory Lymphoma: Findings Jeremy S. Abramson? Molecular Pharmacology
from a Phase 1 Study? and Drug Resistance:
Lymphoid Neoplasms:
Poster I
Date: Saturday,
December 11, 2021 ?
Presentation Time: 5:30
PM - 7:30 PM ?
Location: Georgia World
Congress Center, Hall
B5??
MANIFEST? Disease-Modifying Potential of Srdan Verstovsek, Mohamed E. Salama, John Accepted as poster
BET Inhibitor Pelabresib Mascarenhas, Moshe Talpaz, Ruben Mesa, #2568?
(CPI-0610) as Demonstrated by Alessandro M. Vannucchi, Raajit K. Rampal, Session Name: 634.
Improvements in Bone Marrow Stephen Oh, Horatiu Olteanu, April Chiu, Dong Myeloproliferative
Function and Clinical Activity Chen, Curtis A Hanson, Natalia Curto-García, Syndromes: Clinical and
in Patients With Myelofibrosis - Pietro Taverna, Jike Cui, Oksana Zavidij, Zehua Epidemiological: Poster
Preliminary Data ? Chen, Gozde Colak, Sergey Efuni, Patricia II ?
Keller, Patrick Trojer, Claire Harrison? Date: Sunday, December
12, 2021 ?
Presentation Time: 6:00
PM - 8:00 PM ?
Location: Georgia World
Congress Center, Hall
B5? TAFASITAMAB ASH 2021 ACCEPTED ABSTRACTS
Study Abstract Title Authors Status / Publication # /
Session
RE-MIND2 Tafasitamab plus Lenalidomide Grzegorz S. Nowakowski, Dok Hyun Yoon, Accepted as oral
versus pola-BR, R2, and CAR T: Patrizia Mondello, Erel Joffe, Anthea Peters, presentation
Comparing Outcomes from Isabelle Fleury, Richard Greil, Matthew Ku, #183
RE-MIND2, an Observational, Reinhard Marks, Kibum Kim, Pier Luigi Zinzani, Session Name: 905.
Retrospective Cohort Study in Judith Trotman, Lorenzo Sabatelli, Dan Huang, Outcomes Research-Lymphoid
Relapsed/Refractory Diffuse Eva E. Waltl, Mark Winderlich, Sumeet Malignancies: Lymphoma/CLL
Large B-Cell Lymphoma Ambarkhane, Nuwan C. Kurukulasuriya, Raul Real-World Data
Cordoba, Georg Hess, Gilles Salles Session Date: Saturday,
December 11, 2021 (MORE TO FOLLOW) Dow Jones Newswires
November 04, 2021 09:00 ET (13:00 GMT)
